We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Prescription medication — not a dietary supplement
Danuglipronis a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Most Danuglipron studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 2021–2025 with a typical study size of 411 participants.
Based on 6 studies · 1 meta-analysis · 4 RCTs · 1,288 total participants
Confidence
ModerateBy outcome
Danuglipron has an evidence score of 3.5/10 — emerging evidence based on 6 indexed studies, including 1 meta-analysis. Pfizer's investigational ORAL small-molecule (non-peptide) GLP-1 receptor agonist for type 2 diabetes and obesity. The appeal was a once-daily-style GLP-1 pill, but its development has been TROUBLED: the twice-daily formulation produced strong HbA1c/weight signals alongside very high GI-driven discontinuation, and Pfizer discontinued the twice-daily form over tolerability while a once-daily form was evaluated; a liver-injury signal halted one formulation. Evidence is early metabolic (HbA1c, weight) from phase-1/phase-2 trials — NOT a longevity drug, NOT approved, and NOT a dietary supplement. Listed here for reference only. Representative study: PMID 37852529.
The commonly studied dose of Danuglipron is INVESTIGATIONAL — no approved consumer dose. In trials, danuglipron was dosed orally twice daily WITH food and escalated weekly to target doses (e.g. up to 120-200 mg BID); a modified-release once-daily form was later under evaluation. Not for self-administration; only appropriate within a clinical trial.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Peppermint Oil
Mostly mechanism / observationalEnteric-coated peppermint oil is one of the better-evidenced botanicals in gastroenterology — multiple meta-analyses of randomized trials show it relieves global symptoms and abdominal pain in irritable bowel syndrome (IBS), with smaller but consistent signals for functional dyspepsia (combined with caraway oil). It is an antispasmodic, not a cure.
Collagen
Last reviewed June 2026 · evidence from 6 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Danuglipron (PF-06882961) — oral small-molecule GLP-1 receptor agonist
Pfizer's investigational ORAL small-molecule (non-peptide) GLP-1 receptor agonist for type 2 diabetes and obesity. The appeal was a once-daily-style GLP-1 pill, but its development has been TROUBLED: the twice-daily formulation produced strong HbA1c/weight signals alongside very high GI-driven discontinuation, and Pfizer discontinued the twice-daily form over tolerability while a once-daily form was evaluated; a liver-injury signal halted one formulation. Evidence is early metabolic (HbA1c, weight) from phase-1/phase-2 trials — NOT a longevity drug, NOT approved, and NOT a dietary supplement. Listed here for reference only.
Phase-1 and phase-2 RCTs show real dose-dependent HbA1c and weight reductions, but danuglipron is investigational, unapproved, and its development has been troubled — the twice-daily form was discontinued over GI tolerability (very high adverse-event-driven dropout) and a liver-injury signal halted a once-daily form. Evidence is early metabolic only, with no long-term outcome data.
Danuglipron (development code PF-06882961) is an oral, NON-PEPTIDE small-molecule GLP-1 receptor agonist discovered and developed by Pfizer for type 2 diabetes (T2D) and obesity.
Unlike injectable peptide GLP-1 agonists (semaglutide, liraglutide) or oral semaglutide (which needs an absorption enhancer and empty-stomach dosing), danuglipron is a true small molecule — a 5-fluoropyrimidine/carboxylic-acid chemotype identified via high-throughput screening (Griffith et al., J Med Chem 2022) — that activates the GLP-1 receptor through a binding pocket requiring a primate-specific tryptophan-33 residue, which is why it raised insulin in primates and humans but not rodents.
Mechanistically it drives the same downstream cascade as the injectable GLP-1 peptides: glucose-dependent insulin secretion and glucagon suppression in the pancreas, central appetite suppression/satiety, and slowed gastric emptying.
The clinical evidence is genuinely EARLY and the development story is TROUBLED — an important honesty caveat for this entry. A phase-1 multiple-ascending-dose study (Saxena et al., Nat Med 2021; n=98 T2D on metformin) established tolerable pharmacology with nausea/dyspepsia/vomiting as the dominant adverse events.
The phase-2b T2D trial (Saxena et al., JAMA Netw Open 2023; n=411) showed dose-dependent HbA1c reductions up to a placebo-adjusted -1.16% and body-weight reductions up to -4.17 kg vs placebo at 16 weeks with twice-daily dosing, but with nausea/diarrhea/vomiting as the most common adverse events.
A phase-2b obesity trial (Buckeridge et al., Diabetes Obes Metab 2025; n=628 adults with obesity without diabetes) showed placebo-adjusted weight reductions ranging from -5.0% to -12.9% over 26-32 weeks — but only 39.3% of participants completed treatment and ~38% discontinued because of adverse events, an unusually high attrition that underscores the tolerability problem.
A dedicated dose-escalation tolerability study (Saxena et al., Diabetes Obes Metab 2023) reported discontinuation of 27.3%-72.7% across danuglipron groups (vs 16.7%-18.8% placebo), driven by GI events that tracked target dose rather than starting dose.
A systematic review/meta-analysis pooling orforglipron and danuglipron RCTs (Karakasis et al., Metabolism 2023) confirmed significant HbA1c and weight reductions but ~2.6-fold higher GI adverse events and ~2.9-fold higher discontinuation versus controls.
The development outcome is the honest headline: in 2023 Pfizer discontinued the twice-daily formulation of danuglipron, citing tolerability (high rates of nausea/vomiting) despite the efficacy signal, and shifted to evaluating a once-daily modified-release form; subsequently a liver-injury (drug-induced liver injury) signal in a participant in the once-daily program led Pfizer to halt that formulation as well.
So danuglipron is INVESTIGATIONAL, not approved, with no long-term outcome data, a class thyroid C-cell (medullary carcinoma) concern expected to apply, and a development history dominated by GI tolerability and a hepatic-safety signal.
It is mechanistically interesting as one of the first oral small-molecule GLP-1 agonists, but it is NOT a longevity drug (no lifespan or healthspan data), NOT a dietary supplement, and must never be sourced from grey-market/research-chemical vendors — an unapproved investigational drug bought off-trial carries serious identity, dosing, purity, and hepatic-safety risks.
A small-molecule (non-peptide) agonist of the human GLP-1 receptor, binding a pocket that requires a primate-specific tryptophan-33 residue — orally bioavailable and resistant to the enzymatic degradation that forces peptide GLP-1s to be injected. The single upstream target driving all downstream metabolic effects.
Stimulates insulin release from pancreatic beta cells in a glucose-dependent way and suppresses glucagon, lowering fasting glucose and HbA1c with low intrinsic hypoglycemia risk.
Acts on central appetite circuits to increase satiety and reduce food intake — the driver of the weight loss seen in the phase-2 T2D and obesity trials.
Delays gastric emptying, blunting post-meal glucose spikes and prolonging fullness — and the mechanism behind the dose-dependent nausea/vomiting that dominated tolerability and drove the high trial discontinuation rates.
How Danuglipron works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Tap node to isolate • Pinch to zoom • Tap edge for research
INVESTIGATIONAL — no approved consumer dose. In trials, danuglipron was dosed orally twice daily WITH food and escalated weekly to target doses (e.g. up to 120-200 mg BID); a modified-release once-daily form was later under evaluation. Not for self-administration; only appropriate within a clinical trial.
Loading: Dose was escalated weekly (e.g. starting 2.5-10 mg and stepping up over weeks toward 80-200 mg twice daily) specifically to limit gastrointestinal side effects — done under trial supervision, never self-titrated. Even so, GI-driven discontinuation was high.
Take with food
| Form | Type |
|---|---|
| 💊Oral tablet (investigational) | Recommended |
Never source danuglipron from grey-market / research-chemical vendors — it is an unapproved investigational drug whose own development was halted over a hepatic-safety signal; off-trial product carries serious identity, dosing, purity, and liver-safety risks.
Minimum: 12 weeks
Optimal: 32 weeks
Cycling: Not required
Note: Trial danuglipron was taken twice daily with food and titrated upward gradually under trial supervision. Never self-administer or self-escalate — it is an unapproved investigational drug.
Dose-response data unavailable. The current published research for Danuglipron does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
Dose-dependent HbA1c reductions in type 2 diabetes — up to a placebo-adjusted -1.16% at 16 weeks (phase-2b) — with fasting-glucose reductions alongside.
Placebo-adjusted weight loss up to ~-4.2 kg in T2D and -5.0% to -12.9% in obesity over 26-32 weeks — clinically meaningful, but achieved at doses where GI tolerability was poor.
Nausea, vomiting and diarrhea were the most frequent adverse events and dose-dependent. Discontinuation was unusually high — ~38% of obesity-trial participants quit for adverse events, and up to ~73% in one dose-escalation arm.
Pfizer discontinued the twice-daily formulation over tolerability, then halted a once-daily formulation after a drug-induced liver-injury signal. A real development setback, not a routine class caveat.
Danuglipron is an unapproved drug in clinical development with no long-term outcome data and an unresolved formulation path — listed here for reference only.
Particular caution given the drug-induced liver-injury signal that halted a danuglipron formulation.
Expected to be contraindicated — the GLP-1 class carries a thyroid C-cell tumor warning.
Use caution under specialist guidance, consistent with the GLP-1 class.
Contraindicated — weight loss and an investigational drug are not appropriate in pregnancy.
Not appropriate — it is an unapproved investigational drug whose own development was halted over a hepatic-safety signal; off-trial sourcing carries serious identity, dosing, purity, and liver-safety risks.
Combining a GLP-1 agonist with insulin or sulfonylureas raises hypoglycemia risk; danuglipron alone showed no clinically meaningful severe hypoglycemia in trials.
Delayed gastric emptying can change the absorption of co-administered oral drugs — a class consideration for any GLP-1 agonist.
Tip: Gradual dose titration with food; usually concentrated during dose escalation — but a frequent reason for dropping out in the danuglipron trials
Tip: Slow titration, hydration, dietary adjustment; dose-dependent and a leading cause of the high discontinuation in the trials
Tip: Unusually high — ~38% of obesity-trial participants discontinued for adverse events, and up to ~73% in a high-dose escalation arm; this drove Pfizer to discontinue the twice-daily formulation
Tip: A liver-injury signal in the once-daily program led Pfizer to halt that formulation; a meaningful development-level safety concern, not just a routine class caveat
Timing is flexible for Danuglipron — consistent daily use matters more than the time of day. The phase-1/phase-2 danuglipron formulation was taken twice daily WITH food and titrated upward gradually under trial supervision.
Danuglipron should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are nausea, vomiting / diarrhea, treatment discontinuation due to GI events. Use caution if any of these apply to you: Not an approved medicine — only appropriate within a clinical trial; Hepatic-safety signal: a drug-induced liver-injury signal halted a once-daily formulation in development; Expected: personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) — the GLP-1-class thyroid C-cell concern.
Hydrolyzed peptides that rebuild skin elasticity, reduce joint pain, and strengthen bone density — results build over 8-12 weeks.
Do not combine with another GLP-1 agonist (semaglutide, liraglutide, dulaglutide, tirzepatide, orforglipron) — additive GI risk with no added benefit.
Tip: A GLP-1-class caution; seek urgent care for severe persistent abdominal pain